Queisser Pharma GmbH & Co. KG – Trademark Portfolio
Entity Type: 99
Queisser Pharma GmbH & Co. KG holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include Q, QUEISSER, and DOPPELHERZ SYSTEM. The owner is based in Flensburg.
Schleswiger Str. 74
Flensburg 24941 , DE
Showing of trademarks Trademarks
Trademark Classifications
Queisser Pharma GmbH & Co. KG's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Queisser Pharma GmbH & Co. KG have?
Queisser Pharma GmbH & Co. KG has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending, 1 cancelled.
What trademark classes does Queisser Pharma GmbH & Co. KG file in?
Queisser Pharma GmbH & Co. KG files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Queisser Pharma GmbH & Co. KG's most well-known trademarks?
Queisser Pharma GmbH & Co. KG's registered trademark portfolio includes well-known marks such as Q, QUEISSER, and DOPPELHERZ SYSTEM. These are among 3 currently registered trademarks in the portfolio.
What is Queisser Pharma GmbH & Co. KG's trademark registration success rate?
Queisser Pharma GmbH & Co. KG has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 1 application is pending review.